Ocera Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 72   

Articles published

OCRX 2.58 -0.02 (-0.77%)
price chart
What Will Happen to Ocera Therapeutics Inc Next? The Stock Just Gapped Down
The stock of Ocera Therapeutics Inc (NASDAQ:OCRX) gapped down by $0.11 today and has $2.29 target or 12.00% below today's $2.60 share price.
Ocera Therapeutics Inc Stock Technicals at Critical Inflection Point
This is a technical analysis stock rating for Ocera Therapeutics Inc (NASDAQ:OCRX) . The company has a three bull technical rating which indicates an inflection point.
Ocera Therapeutics Inc Stock Momentum at Critical Inflection Point
This is a momentum stock rating analysis for Ocera Therapeutics Inc (NASDAQ:OCRX) . The company has a three bull momentum rating which indicates an inflection point.
Could Ocera Therapeutics Inc Gain Strenght After Forming Bearish Double Bottom?
The chart of Ocera Therapeutics Inc (OCRX) shows a double bottom with $2.52 target or 10.00% below today's $2.80 share price.
Next Weeks Broker Price Targets For Ocera Therapeutics, Inc. (OCRX)  Fiscal Standard
Ocera Therapeutics: A Speculative Investment
Initiating Coverage of Ocera Therapeutics, a pharmaceutical company with focus on ammonia scavenger drugs in hepatic encephalopathy, with a Speculative Buy rating and price target: $3.40-$5.50.
The Impact Score of Ocera Therapeutics, Inc. (NASDAQ:OCRX) Is 0
Alpha One tracks the most impactfulonline sources that publish content about a particular company on a daily basis. It provides analytics based on the published content.
Ocera Therapeutics Finally Ready To Reward Investors
Furthermore, to bluntly state the obvious, Ocera has had a rough 2014. Investors unfamiliar with the company would probably look at the stock chart and move on to the next assuming that something catastrophic had occurred to warrant such a steep price ...
Ocera Therapeutics, Inc. (NASDAQ:OCRX) Moderate Sell Ratings At 1
Ocera Therapeutics, Inc. (NASDAQ:OCRX) strong sell score is 0 while buy rating count is 0. Moderate sell ratings are 1 while moderate buy calls are 0. Hold ratings count is 0. As many as 0 brokerages initiated coverage on Ocera Therapeutics, Inc.
Ocera Therapeutics Announces Completion of Merger With Tranzyme
SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. ("Ocera"), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. (Nasdaq:TZYM) ("Tranzyme") today announced ...
Related articles »  
Ocera Therapeutics Secures $20 Million Debt Facility from Oxford Finance and ...
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 30, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today ...